Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast

Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Volatility & Risk

Oxford BioMedica has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oxford BioMedica and Immuneering, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford BioMedica	0	0	0	0	0.00
Immuneering	1	0	5	1	2.86

Immuneering has a consensus price target of $16.50, suggesting a potential upside of 192.04%. Given Immuneering’s stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Oxford BioMedica.

Earnings & Valuation

This table compares Oxford BioMedica and Immuneering”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford BioMedica	$164.59 million	5.26	-$46.74 million	N/A	N/A
Immuneering	N/A	N/A	-$56.03 million	($1.38)	-4.09

Oxford BioMedica has higher revenue and earnings than Immuneering.

Insider & Institutional Ownership

67.7% of Immuneering shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Oxford BioMedica and Immuneering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oxford BioMedica	N/A	N/A	N/A
Immuneering	N/A	-43.33%	-39.75%

Summary

Immuneering beats Oxford BioMedica on 6 of the 11 factors compared between the two stocks.

About Oxford BioMedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.